Abstract
The modulation of FXR receptor remains an attractive area in drug discovery to develop novel therapeutic opportunities for liver and metabolic disorders. Despite the large variety of FXR ligands reported so far, only a very restricted number of agonists have entered in clinical settings. In this review article we provide the reader with an overview on the different classes of natural and synthetic ligands that have been developed by academic groups and pharmaceutical companies to target FXR. We discuss their structure-activity relationships, analyzing the binding modes that some of these compounds adopt to interact with the receptor.
Keywords: Bile acid homeostasis, Farnesoid X receptor, Natural ligands, Nuclear receptors, Synthetic ligands.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands
Volume: 14 Issue: 19
Author(s): Andrea Carotti, Maura Marinozzi, Chiara Custodi, Bruno Cerra, Roberto Pellicciari, Antimo Gioiello and Antonio Macchiarulo
Affiliation:
Keywords: Bile acid homeostasis, Farnesoid X receptor, Natural ligands, Nuclear receptors, Synthetic ligands.
Abstract: The modulation of FXR receptor remains an attractive area in drug discovery to develop novel therapeutic opportunities for liver and metabolic disorders. Despite the large variety of FXR ligands reported so far, only a very restricted number of agonists have entered in clinical settings. In this review article we provide the reader with an overview on the different classes of natural and synthetic ligands that have been developed by academic groups and pharmaceutical companies to target FXR. We discuss their structure-activity relationships, analyzing the binding modes that some of these compounds adopt to interact with the receptor.
Export Options
About this article
Cite this article as:
Carotti Andrea, Marinozzi Maura, Custodi Chiara, Cerra Bruno, Pellicciari Roberto, Gioiello Antimo and Macchiarulo Antonio, Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands, Current Topics in Medicinal Chemistry 2014; 14 (19) . https://dx.doi.org/10.2174/1568026614666141112094058
DOI https://dx.doi.org/10.2174/1568026614666141112094058 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endocrinological Aspects of Proteinuria and Podocytopathy in Diabetes: Role of the Aldosterone/Mineralocorticoid Receptor System
Current Diabetes Reviews New Look at Therapeutic Strategies for Blocking Costimulatory Signal in Experimental and Pre-Clinical Transplantation
Current Drug Safety Insights into the Regulation of Renal Hemodynamic Function in Diabetic Mellitus
Current Diabetes Reviews Pros and Cons of Aggressive Blood Pressure Lowering in Patients with Type 2 Diabetes
Current Vascular Pharmacology Bioengineered Polymer/Composites as Advanced Biological Detection of Sorbitol: An Application in Healthcare Sector
Current Topics in Medicinal Chemistry Dipeptide Inhibitors of Thermolysin and Angiotensin I-Converting Enzyme
Current Topics in Medicinal Chemistry Endogenous Repair System of Oxidative Damage of DNA
Current Chemical Biology Pigment Epithelium-Derived Factor (PEDF): Its Potential Therapeutic Implication in Diabetic Vascular Complications
Current Drug Targets Advanced Glycation and Advanced Lipoxidation: Possible Role in Initiation and Progression of Diabetic Retinopathy
Current Pharmaceutical Design Inflammasome as a New Therapeutic Target for Diabetic Complications
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Role of Vascular Endothelial Growth Factor in Kidney Disease
Current Vascular Pharmacology Modulators of Inhibitor of Growth (ING) Family Expression in Development and Disease
Current Drug Targets Suramin Attenuated Inflammation and Reversed Skin Tissue Damage in Experimentally Induced Atopic Dermatitis in Mice
Inflammation & Allergy - Drug Targets (Discontinued) Every Cloud Has a Silver Lining: Proneurogenic Effects of Aβ Oligomers and HMGB-1 via Activation of the RAGE-NF-κB Axis
CNS & Neurological Disorders - Drug Targets Angiotensin-Converting Enzyme Inhibitors in Veterinary Medicine
Current Pharmaceutical Design Increased Risk of Falls, Fall-related Injuries and Fractures in People with Type 1 and Type 2 Diabetes - A Nationwide Cohort Study
Current Drug Safety Caveolin-1: A Promising Therapeutic Target for Diverse Diseases
Current Molecular Pharmacology Antihypertensive Drugs Metabolism: An Update to Pharmacokinetic Profiles and Computational Approaches
Current Pharmaceutical Design Editorial
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Nanoemulsions: A Better Approach for Antidiabetic Drug Delivery
Current Diabetes Reviews